Cao Shunwang, Zhong Fei, Chen Xueying, Ke Sikai, Zhong Xiangrong, Li Tingting, Sha Yanhua, Kang Chunmin, Qin Sheng, Wang Hongmei, Wang Yi, Liao Shuzhi, Ke Peifeng
Department of Laboratory Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China.
Guangzhou Key Laboratory of Translational Medicine on Malignant Tumor Treatment, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, P.R. China.
Mol Med Rep. 2025 Feb;31(2). doi: 10.3892/mmr.2024.13409. Epub 2024 Dec 5.
Long noncoding RNA (lncRNA) PTTG3P has been demonstrated to participate in the development of hepatocellular carcinoma (HCC) by targeting the mRNA PTTG1. The present study aimed to investigate the diagnostic efficacy of serum lncRNA PTTG3P, mRNA PTTG1 and their combination for the diagnosis and prognosis of HCC. A total of 373 participants were enrolled in the present study, including 73 patients with HCC, 100 patients with chronic hepatitis B (CHB), 100 patients with liver cirrhosis (LC) and 100 healthy controls (HCs). The expression levels of serum RNAs were quantified by reverse transcription‑quantitative PCR. The association between serum lncRNA PTTG3P and clinical characteristics was further analyzed. Receiver operating characteristic (ROC) curve and area under curve (AUC) analyses were performed to estimate the diagnostic ability of serum lncRNA PTTG3P, PTTG1 and their combinations with other biomarkers for HCC. The results revealed that the expression levels of lncRNA PTTG3P and mRNA PTTG1 were markedly increased in the serum of patients with HCC and CHB compared with in the serum of HCs. Additionally, the postoperative levels of lncRNA PTTG3P and mRNA PTTG1 were significantly lower than the preoperative concentrations in 36 paired patients with HCC. Spearman's correlation coefficient analysis showed that serum lncRNA PTTG3P was correlated with aspartate transaminase (AST). ROC analysis showed that both lncRNA PTTG3P and mRNA PTTG1 had a significant predictive value for HCC. The AUC values of lncRNA PTTG3P and mRNA PTTG1 alone were 0.636 and 0.634, respectively. Furthermore, combining lncRNA PTTG3P, mRNA PTTG1, α‑fetoprotein (AFP), alanine aminotransferase (ALT), AST, γ‑glutamyl transpeptidase (GGT) and alkaline phosphatase (ALP) significantly increased the AUC value. The best performance was the combination of PTTG3P, PTTG1, AFP, ALT, AST, GGT and ALP with an AUC of 0.959, a sensitivity of 90.4% and a specificity of 98.0%. In conclusion, the combination of serum lncRNA PTTG3P, mRNA PTTG1 and AFP appeared to be a noninvasive biomarker with comparatively high specificity and sensitivity for the diagnosis of HCC.
长链非编码RNA(lncRNA)PTTG3P已被证明可通过靶向mRNA PTTG1参与肝细胞癌(HCC)的发展。本研究旨在探讨血清lncRNA PTTG3P、mRNA PTTG1及其组合对HCC诊断和预后的诊断效能。本研究共纳入373名参与者,包括73例HCC患者、100例慢性乙型肝炎(CHB)患者、100例肝硬化(LC)患者和100名健康对照者(HCs)。通过逆转录定量PCR对血清RNA的表达水平进行定量。进一步分析血清lncRNA PTTG3P与临床特征之间的关联。进行受试者工作特征(ROC)曲线和曲线下面积(AUC)分析,以评估血清lncRNA PTTG3P、PTTG1及其与其他生物标志物组合对HCC的诊断能力。结果显示,与HCs血清相比,HCC和CHB患者血清中lncRNA PTTG3P和mRNA PTTG1的表达水平显著升高。此外,在36例配对的HCC患者中,lncRNA PTTG3P和mRNA PTTG1的术后水平显著低于术前浓度。Spearman相关系数分析表明,血清lncRNA PTTG3P与天冬氨酸转氨酶(AST)相关。ROC分析表明,lncRNA PTTG3P和mRNA PTTG1对HCC均具有显著的预测价值。lncRNA PTTG3P和mRNA PTTG1单独的AUC值分别为0.636和0.634。此外,将lncRNA PTTG3P、mRNA PTTG1、甲胎蛋白(AFP)、丙氨酸转氨酶(ALT)、AST、γ-谷氨酰转肽酶(GGT)和碱性磷酸酶(ALP)联合使用可显著提高AUC值。最佳表现是PTTG3P、PTTG1、AFP、ALT、AST、GGT和ALP的组合,AUC为0.959,敏感性为90.4%,特异性为98.0%。总之,血清lncRNA PTTG3P、mRNA PTTG1和AFP的组合似乎是一种对HCC诊断具有较高特异性和敏感性的非侵入性生物标志物。